<DOC>
	<DOCNO>NCT00057031</DOCNO>
	<brief_summary>The purpose study determine safety efficacy DN-101 ( calcitriol ) patient myelodysplastic syndrome dependent repeat blood transfusion .</brief_summary>
	<brief_title>Study High-Dose Pulse Administration DN-101 ( Calcitriol ) Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>DN-101 experimental drug approve Food Drug Administration ( FDA ) . It newly formulate pill contains high amount calcitriol , naturally occur hormone biologically active form vitamin D. The natural vitamin D find dairy product typical vitamin pill , must chemically change liver kidney calcitriol biologically active . The body normally use small amount calcitriol regulate blood calcium level . However , possible therapeutic effect , MDS patient require much high level calcitriol body produce dietary vitamin D. DN-101 provide MDS patient high dos calcitriol pill form . Laboratory study demonstrate evidence support use calcitriol MDS . High dose calcitriol slow growth leukemic cell ( cancerous cell ) increase growth normal bone marrow cell . Some patient MDS may low level calcitriol bone marrow . Clinical study result patient MDS mixedâ€“ positive negative result . Elevated calcium blood occur frequently prevent use high , potentially therapeutic dos . Novacea test new formulation calcitriol , DN-101 , Phase 1 study . In study maximum tolerate dose DN-101 cause high blood calcium level give weekly several month determine . That dose within range potentially therapeutic MDS patient use MDS study . The purpose study determine HDPA DN-101 treatment : - increase number red blood cell , white blood cell , platelet blood - reduces number blood transfusion - reduces number serious infection require antibiotic - reduces number serious bleed event - improve fatigue</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Diagnosis low intermediate1 risk MDS Dependent monthly blood transfusion No cancer within last 5 year ( cured skin cancer allow ) No heart attack stroke within last 6 month No kidney stone within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>